Shire PLC (SHPG) – Investment Analysts’ Weekly Ratings Updates

Shire PLC (NASDAQ: SHPG) recently received a number of ratings updates from brokerages and research firms:

  • 10/30/2017 – Shire PLC had its “buy” rating reaffirmed by analysts at FBR & Co. They now have a $201.00 price target on the stock.
  • 10/29/2017 – Shire PLC was given a new $225.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 10/27/2017 – Shire PLC had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $222.00 price target on the stock.
  • 10/27/2017 – Shire PLC was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio, acquiring roughly 23% of the total market by the end of Jun 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry so far this year. Estimates have risen ahead of Q3 earnings. The company has a mixed record of earnings surprises in recent quarters.”
  • 10/27/2017 – Shire PLC had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $160.00 price target on the stock.
  • 10/26/2017 – Shire PLC was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 10/20/2017 – Shire PLC was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio, acquiring roughly 23% of the total market by the end of Jun 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry so far this year. Estimates have been stable ahead of Q3 earnings. The company has a mixed record of earnings surprises in recent quarters.”
  • 10/19/2017 – Shire PLC is now covered by analysts at FBR & Co. They set a “buy” rating and a $201.00 price target on the stock.
  • 10/11/2017 – Shire PLC had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $213.00 price target on the stock.
  • 10/8/2017 – Shire PLC had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $245.00 price target on the stock.
  • 10/2/2017 – Shire PLC had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $213.00 price target on the stock.
  • 9/14/2017 – Shire PLC had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $222.00 price target on the stock.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.64 by $0.17. The business had revenue of $3.70 billion for the quarter. Shire PLC had a return on equity of 14.73% and a net margin of 10.95%. The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.17 earnings per share.

The business also recently declared a semiannual dividend, which was paid on Friday, October 20th. Stockholders of record on Friday, September 8th were given a dividend of $0.1527 per share. This represents a dividend yield of 0.21%. The ex-dividend date was Thursday, September 7th. Shire PLC’s payout ratio is 17.23%.

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply